2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Ovarian Neoplasms
94
Small Cell Lung Carcinoma
76
Neuroblastoma
44
Carcinoma, Ovarian Epithelial
43
Fallopian Tube Neoplasms
41
Lung Neoplasms
39
Neoplasms
29
Uterine Cervical Neoplasms
26
Leukemia
20
Brain Neoplasms
18
Leukemia, Myeloid, Acute
17
Recurrence
16
Sarcoma
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Neoplasm Metastasis
13
Lymphoma
12
Central Nervous System Neoplasms
12
Retinoblastoma
11
Glioma
11
Carcinoma, Non-Small-Cell Lung
11
Sarcoma, Ewing
10
Unspecified Adult Solid Tumor, Protocol Specific
8
Neuroectodermal Tumors, Primitive, Peripheral
8
Myelodysplastic Syndromes
8
Medulloblastoma
8
Endometrial Neoplasms
8
Burkitt Lymphoma
8
Lymphoma, Follicular
7
Leukemia, Myelomonocytic, Chronic
7
Blast Crisis
7
Interventions
selinexor
1
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Drug Therapy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
Topotecan
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled